Review Article Open Access
Volume 2 | Issue 4 | DOI: https://doi.org/10.33696/immunology.2.042

Current Advances in CAR T Cell Therapy for Malignant Mesothelioma

  • 1Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK
  • 2Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
+ Affiliations - Affiliations

Corresponding Author

Astero Klampatsa, astero.klampatsa@icr.ac.uk

Received Date: May 30, 2020

Accepted Date: June 22, 2020


Malignant mesothelioma is a relatively rare malignancy arising in the body’s serosal surfaces, with malignant pleural mesothelioma (MPM) being the most common type. It is characterized by local spread within the thorax, poor prognosis and resistance to treatment. The development of various immunotherapeutic options has provided a new way- and hope- in treating cancer patients. Chimeric antigen receptor (CAR) T cell therapy has been proven very successful in treating hematological cancers, like leukemias and lymphomas, and its use is now being tested in solid tumors. CARs that recognize and bind to a specific tumor-associated antigen on the tumor’s cell surface, are engineered and transduced into T cells. Interaction of the CAR T cell with the tumor then results in T cell activation and subsequent tumor cell lysis. In this review, we provide a current update on our previous comprehensive study summarizing the CAR T cell preclinical studies and clinical trials in MM, and discuss the future perspectives of CAR T cell therapy in this disease.


Chimeric antigen receptor T cells; Mesothelioma, Adoptive cell transfer; Solid tumor; Tumor microenvironment

Author Information X